Zydus dedicated to life

Press Release

Press Release Press Release
Press Release
Press Release Press Release
Press Release Press Release

# Zydus receives final approval for Etodolac ER Tablets

Ahmedabad, 30 January 2014

Zydus Cadila has received the final approval from the USFDA to market Etodolac Extended-release Tablets USP, 400 mg, 500 mg, and 600 mg. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis

The group now has 88 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.

***

For further information please contact :
**The Corporate Communications Department**

**Cadila Healthcare Limited**
'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com